Tags

Type your tag names separated by a space and hit enter

Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up.
Hepatology. 2012 Aug; 56(2):516-22.Hep

Abstract

Persistence of seropositivity conferred by hepatitis A vaccine administered to children <2 years of age is unknown and passively transferred maternal antibodies to hepatitis A virus (maternal anti-HAV) may lower the infant's immune response to the vaccine. One hundred ninety-seven infants and young children were randomized into three groups to receive a two-dose hepatitis A vaccine: group 1 at 6 and 12 months, group 2 at 12 and 18 months, and group 3 at 15 and 21 months of age. Within each group, infants were randomized by maternal anti-HAV status. Anti-HAV levels were measured at 1 and 6 months and at 3, 5, 7, and 10 years after the second dose of hepatitis A vaccination. Children in all groups had evidence of seroprotection (>10 mIU/mL) at 1 month after the second dose. At 10 years, all children retained seroprotective anti-HAV levels except for only 7% and 11% of children in group 1 born to anti-HAV-negative and anti-HAV-positive mothers, respectively, and 4% of group 3 children born to anti-HAV-negative mothers. At 10 years, children born to anti-HAV-negative mothers in group 3 had the highest geometric mean concentration (GMC) (97 mIU/mL; 95% confidence interval, 71-133 mIU/mL) and children born to anti-HAV-positive mothers in group 1 had the lowest GMC (29 mIU/mL; 95% confidence interval, 20-40 mIU/mL). Anti-HAV levels through 10 years of age correlated with initial peak anti-HAV levels (tested at 1 month after the second dose).

CONCLUSION

The seropositivity induced by hepatitis A vaccine given to children <2 years of age persists for at least 10 years regardless of presence of maternal anti-HAV.

Authors+Show Affiliations

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

22371069

Citation

Sharapov, Umid M., et al. "Persistence of Hepatitis a Vaccine Induced Seropositivity in Infants and Young Children By Maternal Antibody Status: 10-year Follow-up." Hepatology (Baltimore, Md.), vol. 56, no. 2, 2012, pp. 516-22.
Sharapov UM, Bulkow LR, Negus SE, et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology. 2012;56(2):516-22.
Sharapov, U. M., Bulkow, L. R., Negus, S. E., Spradling, P. R., Homan, C., Drobeniuc, J., Bruce, M., Kamili, S., Hu, D. J., & McMahon, B. J. (2012). Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology (Baltimore, Md.), 56(2), 516-22. https://doi.org/10.1002/hep.25687
Sharapov UM, et al. Persistence of Hepatitis a Vaccine Induced Seropositivity in Infants and Young Children By Maternal Antibody Status: 10-year Follow-up. Hepatology. 2012;56(2):516-22. PubMed PMID: 22371069.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. AU - Sharapov,Umid M, AU - Bulkow,Lisa R, AU - Negus,Susan E, AU - Spradling,Philip R, AU - Homan,Chriss, AU - Drobeniuc,Jan, AU - Bruce,Michael, AU - Kamili,Saleem, AU - Hu,Dale J, AU - McMahon,Brian J, Y1 - 2012/06/11/ PY - 2011/08/08/received PY - 2012/02/17/accepted PY - 2012/2/29/entrez PY - 2012/3/1/pubmed PY - 2012/10/12/medline SP - 516 EP - 22 JF - Hepatology (Baltimore, Md.) JO - Hepatology VL - 56 IS - 2 N2 - UNLABELLED: Persistence of seropositivity conferred by hepatitis A vaccine administered to children <2 years of age is unknown and passively transferred maternal antibodies to hepatitis A virus (maternal anti-HAV) may lower the infant's immune response to the vaccine. One hundred ninety-seven infants and young children were randomized into three groups to receive a two-dose hepatitis A vaccine: group 1 at 6 and 12 months, group 2 at 12 and 18 months, and group 3 at 15 and 21 months of age. Within each group, infants were randomized by maternal anti-HAV status. Anti-HAV levels were measured at 1 and 6 months and at 3, 5, 7, and 10 years after the second dose of hepatitis A vaccination. Children in all groups had evidence of seroprotection (>10 mIU/mL) at 1 month after the second dose. At 10 years, all children retained seroprotective anti-HAV levels except for only 7% and 11% of children in group 1 born to anti-HAV-negative and anti-HAV-positive mothers, respectively, and 4% of group 3 children born to anti-HAV-negative mothers. At 10 years, children born to anti-HAV-negative mothers in group 3 had the highest geometric mean concentration (GMC) (97 mIU/mL; 95% confidence interval, 71-133 mIU/mL) and children born to anti-HAV-positive mothers in group 1 had the lowest GMC (29 mIU/mL; 95% confidence interval, 20-40 mIU/mL). Anti-HAV levels through 10 years of age correlated with initial peak anti-HAV levels (tested at 1 month after the second dose). CONCLUSION: The seropositivity induced by hepatitis A vaccine given to children <2 years of age persists for at least 10 years regardless of presence of maternal anti-HAV. SN - 1527-3350 UR - https://www.unboundmedicine.com/medline/citation/22371069/Persistence_of_hepatitis_A_vaccine_induced_seropositivity_in_infants_and_young_children_by_maternal_antibody_status:_10_year_follow_up_ L2 - https://doi.org/10.1002/hep.25687 DB - PRIME DP - Unbound Medicine ER -